• DOI:10.1124/dmd.117.075341
Corpus ID: 42285855

Inhibition of the all-trans Retinoic Acid (atRA) Hydroxylases CYP26A1 and CYP26B1 Results in Dynamic, Tissue-Specific Changes in Endogenous atRA Signaling

@article{Stevison2017InhibitionOT,
  title={Inhibition of the all-trans Retinoic Acid (atRA) Hydroxylases CYP26A1 and CYP26B1 Results in Dynamic, Tissue-Specific Changes in Endogenous atRA Signaling},
  author={F. Stevison and C. Hogarth and S. Tripathy and Travis M. Kent and N. Isoherranen},
  journal={Drug Metabolism and Disposition},
  year={2017},
  volume={45},
  pages={846 - 854}
}

F. Stevison, C. Hogarth, +2 authors N. Isoherranen

Published 2017

Biology, Medicine

Drug Metabolism and Disposition

All-trans retinoic acid (atRA), the active metabolite of vitamin A, is a ligand for several nuclear receptors and acts as a critical regulator of many physiologic processes. The cytochrome P450 family 26 (CYP26) enzymes are responsible for atRA clearance, and are potential drug targets to increase concentrations of endogenous atRA in a tissue-specific manner. Talarozole is a potent inhibitor of CYP26A1 and CYP26B1, and has shown some success in clinical trials. However, it is not known what… CONTINUE READING

View on Publisher

dmd.aspetjournals.org

Save to Library

Create Alert

Cite

Launch Research Feed